Altemeyer: Buildings, facilities play role in fighting ‘superbugs’
Design can help thwart antibiotic-resistant bacteria
Design can help thwart antibiotic-resistant bacteria
Major Health Partners will construct an $89 million hospital on the north edge of Shelbyville, after nearly a decade of shifting services to that location. According to the Shelbyville News, Major’s board voted Sept. 22 to build a 300,000-square-foot facility in the Intelliplex technology park along Interstate 74 and move from downtown Shelbyville. Construction on the project could begin as early as next month and take about two years to complete. Major first revealed detailed plans for the hospital six weeks ago, but the project could not go forward until the board’s 6-0 vote. The hospital will include 56 beds, all in private rooms, and 38 outpatient observation beds. Major’s current hospital has 72 beds in mostly semi-private rooms. When completed, the new complex will also have four operating rooms and house 57 physicians and a staff of about 930.
Researchers at Purdue University and the Indiana University School of Medicine have received a $3.7 million grant to study how blueberries reduce bone loss in postmenopausal women. The five-year grant from the National Institutes of Health's National Center for Complementary and Alternative Medicine will pay for researchers to conduct human trials aimed at finding the most effective varieties and dosage levels of blueberriers for reducing bone loss. “This is one of the most compelling avenues to pursue in natural products research because blueberries would be a new alternative to osteoporosis drugs and their side effects,” said Connie Weaver, the head of Purdue’s department of nutrition science and one of the grant recipients.
Bernard Health, a health benefits brokerage firm based in Tennessee, opened its second retail store in Indianapolis last week. The 1,270-square-foot store is downtown on Pennsylvania Street, just north of Washington Street. Bernard, which now employs seven here in Indianapolis, opened its first local retail store in the Nora neighborhood in 2012 and now has 12 stores nationwide. For a fee, Bernard helps individuals and small businesses evaluate and purchase health benefits. It is one of several new models being tried out by benefits brokers in Indiana to adapt to new rules and opportunities under Obamacare.
The Indiana University School of Medicine received gifts totaling $1 million on the 40th anniversary of Dr. Larry Einhorn’s discovery of a drug combination therapy that nearly cured testicular cancer. In September 1974, Einhorn, a professor at the IU medical school, first tested the cancer drug cisplatin with two other cancer drugs—a combination that boosted survival rates from the cancer from about 20 percent to 95 percent. According to the medical school, 300,000 patients have survived testicular cancer after receiving the drug therapy Einhorn discovered. The most famous is Lance Armstrong, the cycling champion stripped of his victories after admitting to doping. The gifts will help launch a gene sequencing program among survivors so future patients can be given treatments that reduce side effects and complications. Half the donated money came from A. Farhad Moshiri of Monaco, who previously donated $2 million to IU. Another $300,000 will come from the children of local real estate magnate Sidney Eskenazi and his wife, Lois.
Indianapolis-based private investment company LDI Ltd. has acquired a small biotech manufacturer in a deal it says could be the launching point for many more acquisitions.
The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes, which affects more than 26 million Americans.
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
Companion Diagnostics Inc., a biotech company that relocated to Indiana from Connecticut in 2010, has entered bankruptcy reorganization while it tries to develop a therapy for inflammation.
The drug company said Thursday its drug ixekizumab cleared away skin inflammation in six times as many patients as the blockbuster drug Enbrel. Lilly is in a race to bring the first in a new-class of psoriasis treatments to market.
Founders of Chondrial Therapeutics believe that if further testing validates their treatment for Friedreich’s ataxia, it could be a blockbuster with annual sales topping $1 billion.
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
Indiana’s autism therapists say their prospects are cloudy after the state’s largest health insurer, Anthem Blue Cross and Blue Shield, cut payments 40 percent and took a harder line on paying for therapy for school-age children.
Endocyte Inc.’s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won’t be able to sell it until issues are resolved at a German plant.
Lawmakers' efforts to crack down on the use of Indiana tanning beds this year are part of a national push to limit young people's exposure to risks that include skin cancer.
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
Eli Lilly and Co., Pfizer Inc. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis.